MedTrace Logo

Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression

NCT04485845 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2020-07-24

No results posted yet for this study

Summary

Several crosssectional and prospective studies have shown that metabolic syndrome and its related components are associated with both prevalent and incident CKD .

Although the mechanisms for these cardiovascular benefits of Metformin and vildagliptin remain unclear, they extend well beyond glycemic lowering, and therefore are probably best considered diverse "cardiometabolic" pharmaceuticals rather than simply type 2 diabetes drugs.

Metformin and vildagliptin have known vasculoprotective actions, but the value of these drugs on drug-naïve diabetic patients during 24 week use warrants investigation. The investigator's purpose was to observe their effects on weight control, Cardiometabolic Risk Factors, Metabolic Syndrome risk, and diabetic nephrooathy Progression.

Conditions

  • Metabolic Syndrome
  • Diabete Type 2
  • Kidney Insufficiency

Interventions

DRUG

Vildagliptin

to compare the effect of both metformin and vildagliptin on the progression of diabetes and metabolic complications and risk factors

DRUG

Captopril Tablets

used to treat hypertension in metabolic syndrome patients and as a renal protector

DRUG

MetFORMIN 500 Mg Oral Tablet

antihyperglycemic drug for elevated plasma glucose level and help in weight loss for patients suffering from diabetes or metabolic syndrome

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Dalia Zaafar, PhD · Lecturer of clinical pharmacology and toxicology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2020-08-30
Completion
2020-09-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04485845 on ClinicalTrials.gov